Mesoblast (MESO) Depreciation & Amortization (CF) (2016 - 2023)
Mesoblast (MESO) reported Depreciation & Amortization (CF) of -$991000.0 for Q1 2023, up 11.04% on a YoY basis from -$892460.8 in Q1 2022, and up 8.83% sequentially from -$1.1 million in Q4 2022.
Mesoblast (MESO) Depreciation & Amortization (CF) (2016 - 2023) Analysis & Trends
Mesoblast (MESO) has 8 years of Depreciation & Amortization (CF) data on file, last reported at -$991000.0 in Q1 2023.
- For the quarter ending Q1 2023, Depreciation & Amortization (CF) rose 11.04% year-over-year to -$991000.0; the trailing twelve-month figure through Jun 2024 stood at -$991000.0 (up 68.87% YoY), and the FY2017 full-year result was -$3.1 million, changed N/A from the prior year.
- Depreciation & Amortization (CF) rose to -$991000.0 in Q1 2023, from -$1.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.1 million in Q4 2020 to a low of -$1.1 million in Q1 2022.
- A 5-year average of -$515538.5 and a median of -$991000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slumped 253.25% in 2019 and surged 453.41% in 2020, its largest moves.
- Tracing MESO's Depreciation & Amortization (CF) over 5 years: stood at -$865000.0 in 2019, then surged by 453.41% to $3.1 million in 2020, then sank by 136.05% to -$1.1 million in 2021, then grew by 1.36% to -$1.1 million in 2022, then increased by 8.83% to -$991000.0 in 2023.
- Business Quant data shows MESO's Depreciation & Amortization (CF) at -$991000.0 in Q1 2023, -$1.1 million in Q4 2022, and -$1.1 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Mesoblast | 19.81 Bn | 19.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -991,000.00 |
| Mar 31, 2023 | -991,000.00 |
| Dec 31, 2022 | -1.09 Mn |
| Dec 31, 2022 | -1.09 Mn |
| Sep 30, 2022 | -1.11 Mn |
| Sep 30, 2022 | -1.11 Mn |
| Mar 31, 2022 | -1.11 Mn |
| Mar 31, 2022 | -1.11 Mn |
| Dec 31, 2021 | -1.10 Mn |
| Dec 31, 2021 | -1.10 Mn |
| Sep 30, 2021 | -1.09 Mn |
| Sep 30, 2021 | -1.09 Mn |
| Mar 31, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.08 Mn |
| Dec 31, 2020 | 3.06 Mn |
| Dec 31, 2020 | 3.06 Mn |
| Sep 30, 2020 | 1.01 Mn |
| Sep 30, 2020 | 1.01 Mn |
| Mar 31, 2020 | -945,000.00 |
| Mar 31, 2020 | -945,000.00 |